Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma

This study is testing a targeted radiation therapy called TLX101-Tx (which uses a radioactive amino acid to seek out and irradiate brain tumor cells from the inside) combined with standard treatment for people whose glioblastoma — the most aggressive type of brain tumor — has come back for the first time after initial treatment. **You may be eligible if...** - You are 18 or older - You have glioblastoma that has been confirmed to have returned after first-line treatment - Your tumor is visible on both MRI and a specific amino acid PET scan (FET-PET) - Your general health is adequate (ECOG 0–2 or KPS ≥70) - You had your first-line treatment (surgery and radiotherapy) at least 3 months ago - Your blood, liver, and kidney function are adequate **You may NOT be eligible if...** - You had brain radiation within the past 3 months - You received bevacizumab within the past 6 weeks - You have an implanted device that is incompatible with MRI or PET scans - You have active severe infection (tuberculosis, hepatitis B or C) - You have phenylketonuria (a metabolic condition that affects amino acid processing) - You have ongoing grade 2 or higher side effects from your previous treatment - You have participated in another experimental study within 90 days Talk to your doctor to see if this trial is right for you.